A Study to Evaluate the Safety and Tolerability of ILB-202

Phase 1 Completed 18 enrolled ILIAS Biologics Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of ILB-202 Administered Intravenously as Single Ascending Doses to Healthy Participants. Male or female subjects aged 18 to 50 years (inclusive) who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Timeline

Start: 2023-05-16
Primary completion: 2023-10-04
Completion: 2023-10-04

Publications

Hyun S, Choi H, Sub Y, Hong D, Ahn SH, Choi K, Ryu S, Kim Y, Park C, Gee HY, Choi C. Safety and Anti-Inflammatory Effects of Engineered Extracellular Vesicles (ILB-202) for NF-kappaB Inhibition: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial. J Extracell Vesicles. 2025 Sep;14(9):e70141. doi: 10.1002/jev2.70141.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ILB-202	Other / unclassified	—	Intravenous

Indications

No indication recorded.